Company Filing History:
Years Active: 2014
Title: **Florence Dal Degan: Innovator in Amyloid-Beta Vaccine Development**
Introduction
Florence Dal Degan is a prominent inventor based in Hørsholm, Denmark, known for her significant contributions to the field of immunology. With a focus on combating diseases characterized by the deposition of amyloid, Florence has made strides in developing innovative solutions that leverage her expertise in biomedical research.
Latest Patents
Florence holds a valuable patent for an **Amyloid-beta polypeptide vaccine**. This patent discloses novel methods and compositions aimed at combating diseases associated with amyloid deposition. The methods involve immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Notably, the immunization is facilitated through the administration of analogs of autologous APP or Aβ that can induce antibody production against the amyloidogenic polypeptides. An especially preferred immunogen in her invention is the modified autologous Aβ, which includes the introduction of single or a few foreign, immunodominant T-cell epitopes.
Career Highlights
Florence is currently employed by H. Lundbeck A/S, a Danish pharmaceutical company renowned for its focus on brain diseases. Her role at Lundbeck allows her to contribute significantly to research and development in the field of neurological health, supporting advancements in treatment options for patients suffering from various conditions.
Collaborations
Throughout her career, Florence has collaborated with esteemed colleagues such as Peter Birk Rasmussen and Martin Roland Jensen. These collaborations highlight the importance of teamwork in the pursuit of innovative medical solutions and underscore the collective effort required to advance research in her field.
Conclusion
Florence Dal Degan exemplifies the spirit of innovation and dedication within the scientific community. Her pioneering work on the amyloid-beta polypeptide vaccine stands as a testament to her commitment to improving healthcare outcomes for individuals affected by amyloid-related diseases. Her contributions not only advance scientific knowledge but also hold the potential for significant therapeutic impact.